文献速递间质性肺疾病

霉酚酸酯与硫唑嘌呤在纤维化间质性肺疾病中的应用

Mycophenolate and azathioprine in fibrotic interstitial lung disease.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01

本研究采用克隆-删失-加权框架模拟随机对照试验,纳入2270例纤维化间质性肺疾病患者,评估6个月内启动免疫抑制(霉酚酸酯或硫唑嘌呤)对3年无移植生存和肺功能轨迹的影响。结果显示免疫抑制未改善任何亚型的生存,且在非IPF特发性间质性肺炎和纤维化过敏性肺炎中与更差生存相关,肺功能轨迹无差异。

要点

  • 免疫抑制未改善非IPF IIP、fHP或CTD-ILD的3年无移植生存。
  • 非IPF IIP中免疫抑制与更差生存相关(HR=1.38;95%CI 1.04-1.84)。
  • fHP中免疫抑制与更差生存相关(HR=1.62;95%CI 1.09-2.40)。

核心结论

  • 免疫抑制启动对3年无移植生存或肺功能轨迹无获益证据,且在部分纤维化ILD亚型中与更高死亡率相关。

研究设计与样本

  • 多中心回顾性研究,采用克隆-删失-加权框架模拟随机对照试验,纳入2270例纤维化ILD患者。

主要发现

  • 非IPF IIP中18%(186/1022)、fHP中30%(162/544)、CTD-ILD中31%(221/704)的患者在入组6个月内启动免疫抑制。
  • 免疫抑制在任何ILD亚型中均与生存改善无关,但在非IPF IIP中与更差生存相关(HR=1.38;95%CI 1.04-1.84),在fHP中亦与更差生存相关(HR=1.62;95%CI 1.09-2.40)。
  • 免疫抑制在任何ILD亚型中均与肺功能轨迹无差异相关。

临床怎么用

  • 对于非IPF IIP和fHP患者,启动霉酚酸酯或硫唑嘌呤前应充分权衡潜在风险,不宜常规期望改善长期生存。

局限性

  • 本研究为回顾性观察性设计,虽采用克隆-删失-加权方法模拟随机试验,仍需前瞻性随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Immunosuppression is routinely used for non-idiopathic pulmonary fibrosis (IPF) interstitial lung diseases (ILDs), despite limited trial evidence and unclear impact on long-term outcomes. OBJECTIVES: To evaluate whether mycophenolate or azathioprine improves 3-year transplant-free survival and lung function trajectory in fibrotic ILD, including non-IPF idiopathic interstitial pneumonia (IIP), fibrotic hypersensitivity pneumonitis (fHP), and connective tissue disease (CTD)-associated ILD. METHODS: We employed a clone-censor-weighting framework to emulate a randomized controlled trial in this multicenter retrospective study. Each patient was cloned and assigned to immunosuppression initiation within 6 months of enrollment or no initiation strategies and censored when the assigned strategy deviated from observed treatment. Stabilized inverse probability treatment and censoring weights were used. MEASUREMENTS: The primary endpoint was 3-year transplant-free survival assessed with weighted Cox models across treatment strategies. Weighted generalized estimating equations were used to model lung function trajectory. MAIN RESULTS: Among 2270 included patients, 18% (186/1022) with non-IPF IIP, 30% (162/544) with fHP, and 31% (221/704) with CTD-ILD were initiated on immunosuppression within 6 months. Immunosuppression was not associated with improved survival within any ILD subtype but was associated with worse survival in non-IPF IIP (hazard ratio [HR] = 1.38; 95% CI, 1.04-1.84) and fHP (HR = 1.62; 95% CI, 1.09-2.40). Immunosuppression was not associated with differential lung function trajectory within any ILD subtype. CONCLUSIONS: In this study, immunosuppression initiation showed no evidence of benefit for 3-year transplant-free survival or lung function and was associated with higher mortality in select fibrotic ILD subtypes. Prospective randomized controlled trials are needed to inform patient care.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Pugashetti JV, Jee AS, Yu AR, et al. Mycophenolate and azathioprine in fibrotic interstitial lung disease. Am J Respir Crit Care Med. 2026. PMID: 42432856. doi:10.1093/ajrccm/aamag362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。